Ebert, ThomasAnker, Stefan D.Ruilope Urioste, Luis MiguelFioretto, PaolaFonseca, VivianUmpierrez, Guillermo E.Birkenfeld, Andreas L.Lawatscheck, RobertScott, CharlieEt al.2025-07-312025-07-312024Ebert, T., Anker, S. D., Ruilope, L. M., Fioretto, P., Fonseca, V., Umpierrez, G. E., Birkenfeld, A. L., Lawatscheck, R., Scott, C., Rohwedder, K., Rossing, P., & FIDELIO-DKD and FIGARO-DKD Investigators. (2024). Outcomes with finerenone in patients with chronic kidney disease and type 2 diabetes by baseline insulin resistance. Diabetes Care, 47(3), 362-370. https://doi.org/10.2337/dc23-14200149-59921935-5548https://hdl.handle.net/11268/16065To explore whether insulin resistance, assessed by estimated glucose disposal rate (eGDR), is associated with cardiorenal risk and whether it modifies finerenone efficacy. Insulin resistance was associated with increased cardiovascular (but not kidney) risk and did not modify finerenone efficacy.engDiabetes Mellitus Tipo 2Enfermedades RenalesResistencia a la Insulinajournal article10.2337/dc23-1420embargoed accessTratamiento médicoInvestigación médicaPatologíaGoal 3: Ensure healthy lives and promote well-being for all at all agesGoal 4: Quality education